Larvol Delta - Century-Therapeutics-Receives-Study-May-Proceed-Notication-from-FDA-for-CNTY101-the-First-Allogeneic-Cell-Therapy-Product-Candidate-Engineered-to-Overcome-Three-Major-Pathways-of-Host-vs-Graft-Rejection

CNTY-101 - Century Therap

https://www.globenewswire.com/news-release/2022/08/25/2504489/0/en/Century-Therapeutics-Receives-Study-May-Proceed-Notification-from-FDA-for-CNTY-101-the-First-Allogeneic-Cell-Therapy-Product-Candidate-Engineered-to-Overcome-Three-Major-Pathways-o.html

Aug 25, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next